TCG Crossover Management, LLC
13F Reported Value
ⓘ$4.2B
Holdings
54
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
TCG Crossover Management, LLC disclosed 54 positions worth $4.2B in its Form 13F-HR for Q2 2026, led by $ABVX (Abivax S.A.) at 19.2% of the equity portfolio, followed by $TNGX and $CGON. During the quarter the fund opened 12 new positions and exited 7 — including a new stake in $ZLAB and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (99.8% of disclosed assets). All figures are sourced directly from TCG Crossover Management, LLC’s Form 13F-HR filing with the SEC under CIK 1839948.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$800.6M6,007,834 sh - 17.6#2,824
Quality
$283.9M9,081,201 sh - 27.0#2,595
Quality
$260.8M3,670,206 sh - —
Quality
$187.9M4,854,436 sh - —
Quality
$171.8M4,457,988 sh - —
Quality
$168.7M1,900,582 sh - 22.6
Quality
$163.4M1,676,624 sh - 35.0
Quality
$124.3M1,062,049 sh - —
Quality
$116.6M6,137,627 sh - 8.7
Quality
$112.1M6,243,812 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Abivax S.A.$ABVX | — | $800.6M | 6,007,834 |
 Tango Therapeutics, Inc.$TNGX | 17.6#2,824 | $283.9M | 9,081,201 |
 CG Oncology, Inc.$CGON | 27.0#2,595 | $260.8M | 3,670,206 |
 Cogent Biosciences, Inc.$COGT | — | $187.9M | 4,854,436 |
 Immunovant, Inc.$IMVT | — | $171.8M | 4,457,988 |
 Spyre Therapeutics, Inc.$SYRE | — | $168.7M | 1,900,582 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $163.4M | 1,676,624 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0 | $124.3M | 1,062,049 |
 Zai Lab Ltd$ZLAB | — | $116.6M | 6,137,627 |
 Amylyx Pharmaceuticals, Inc.$AMLX | 8.7 | $112.1M | 6,243,812 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of TCG Crossover Management, LLC's 54 positions.
Showing top 10 of 54 holdings.
Sector Allocation
Healthcare
$4.2B
Financials
$7.6M
Full Holdings — TCG Crossover Management, LLC (Q2 2026)
All 54 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ABVX | Abivax S.A. | $800.6M | 19.2% | -7% | — |
| 2 | $TNGX | Tango Therapeutics, Inc. | $283.9M | 6.8% | -14% | 17.6 |
| 3 | $CGON | CG Oncology, Inc. | $260.8M | 6.3% | +0% | 27 |
| 4 | $COGT | Cogent Biosciences, Inc. | $187.9M | 4.5% | -2% | — |
| 5 | $IMVT | Immunovant, Inc. | $171.8M | 4.1% | +0% | — |
| 6 | $SYRE | Spyre Therapeutics, Inc. | $168.7M | 4.1% | +0% | — |
| 7 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $163.4M | 3.9% | +0% | 22.6 |
| 8 | $MIRM | Mirum Pharmaceuticals, Inc. | $124.3M | 3.0% | +0% | 35 |
| 9 | $ZLAB | Zai Lab Ltd | $116.6M | 2.8% | NEW | — |
| 10 | $AMLX | Amylyx Pharmaceuticals, Inc. | $112.1M | 2.7% | +0% | 8.7 |
| 11 |  $GLUE | Monte Rosa Therapeutics, Inc. | $111.9M | 2.7% | +0% | 30.3 |
| 12 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $110.2M | 2.6% | +0% | 53.2 |
| 13 |  $VOR | Vor Biopharma Inc. | $104.4M | 2.5% | +0% | — |
| 14 |  $TYRA | Tyra Biosciences, Inc. | $103.8M | 2.5% | +0% | — |
| 15 |  $DYN | Dyne Therapeutics, Inc. | $102.5M | 2.5% | +0% | — |
| 16 |  $IRON | Disc Medicine, Inc. | $98.1M | 2.4% | +0% | — |
| 17 |  $RLAY | Relay Therapeutics, Inc. | $80.0M | 1.9% | +0% | 19.5 |
| 18 |  $SVRA | Savara Inc | $76.2M | 1.8% | +0% | — |
| 19 |  $AURA | Aura Biosciences, Inc. | $67.7M | 1.6% | NEW | — |
| 20 |  $RVMD | Revolution Medicines, Inc. | $63.8M | 1.5% | -41% | — |
| 21 |  $TRAX | First Tracks Biotherapeutics, Inc. | $58.3M | 1.4% | NEW | — |
| 22 |  $KOD | Kodiak Sciences Inc. | $56.3M | 1.4% | +0% | — |
| 23 |  $AVTX | Avalo Therapeutics, Inc. | $55.8M | 1.3% | +309% | 11.7 |
| 24 |  $LBRX | LB PHARMACEUTICALS INC | $47.0M | 1.1% | -21% | — |
| 25 |  $IPSC | Century Therapeutics, Inc. | $43.4M | 1.0% | +0% | 33.5 |
| 26 |  $TECX | Tectonic Therapeutic, Inc. | $41.4M | 1.0% | +0% | — |
| 27 |  $XNCR | Xencor Inc | $39.5M | 0.9% | +0% | 11.6 |
| 28 |  $SRZN | Surrozen, Inc./DE | $38.2M | 0.9% | +0% | — |
| 29 |  $EDIT | Editas Medicine, Inc. | $36.0M | 0.9% | NEW | 33.4 |
| 30 |  $MBX | MBX Biosciences, Inc. | $35.9M | 0.9% | +0% | — |
| 31 |  $PHVS | Pharvaris N.V. | $34.9M | 0.8% | NEW | — |
| 32 |  $SLN | Silence Therapeutics plc | $33.3M | 0.8% | +0% | — |
| 33 |  $IFRX | InflaRx N.V. | $32.5M | 0.8% | NEW | — |
| 34 |  $ALT | Altimmune, Inc. | $30.4M | 0.7% | NEW | 8 |
| 35 |  $JANX | Janux Therapeutics, Inc. | $27.5M | 0.7% | +0% | 30.1 |
| 36 |  $CATX | Perspective Therapeutics, Inc. | $27.0M | 0.7% | +0% | — |
| 37 |  $AGMB | Agomab Therapeutics NV | $26.7M | 0.6% | +0% | — |
| 38 |  $BHVN | Biohaven Ltd. | $26.5M | 0.6% | -62% | — |
| 39 |  $AKTS | Aktis Oncology, Inc. | $22.5M | 0.5% | NEW | — |
| 40 |  $ALEC | Alector, Inc. | $20.1M | 0.5% | +0% | 10.9 |
| 41 |  $FBRX | Forte Biosciences, Inc. | $19.6M | 0.5% | NEW | — |
| 42 |  $MNPR | Monopar Therapeutics | $18.8M | 0.5% | +54% | — |
| 43 |  $OCUL | OCULAR THERAPEUTIX, INC | $16.2M | 0.4% | +0% | 8.4 |
| 44 |  $ADCT | ADC Therapeutics SA | $12.2M | 0.3% | +0% | 21.8 |
| 45 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $11.7M | 0.3% | -57% | — |
| 46 |  $TRDA | Entrada Therapeutics, Inc. | $7.8M | 0.2% | -54% | 7.3 |
| 47 |  $CGEM | Cullinan Therapeutics, Inc. | $7.4M | 0.2% | +0% | — |
| 48 |  $ARVN | ARVINAS, INC. | $5.9M | 0.1% | -70% | 36.6 |
| 49 |  $KRRO | Korro Bio, Inc. | $5.5M | 0.1% | +0% | 14.1 |
| 50 |  $RACC | Research Alliance Corp III | $5.3M | 0.1% | NEW | — |
| 51 |  $LONA | LeonaBio, Inc. | $4.3M | 0.1% | +0% | — |
| 52 |  $JATT | JATT II Acquisition Corp. | $2.3M | 0.1% | NEW | — |
| 53 |  $CNTX | Context Therapeutics Inc. | $1.5M | 0.0% | +0% | — |
| 54 |  $EIKN | Eikon Therapeutics, Inc. | $494,621 | 0.0% | NEW | — |
New Positions (12)
$ZLAB Zai Lab Ltd$116.6M$AURA Aura Biosciences, Inc.$67.7M$TRAX First Tracks Biotherapeutics, Inc.$58.3M$EDIT Editas Medicine, Inc.$36.0M$PHVS Pharvaris N.V.$34.9M$IFRX InflaRx N.V.$32.5M$ALT Altimmune, Inc.$30.4M$AKTS Aktis Oncology, Inc.$22.5M$FBRX Forte Biosciences, Inc.$19.6M$RACC Research Alliance Corp III$5.3M$JATT JATT II Acquisition Corp.$2.3M$EIKN Eikon Therapeutics, Inc.$494,621
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for TCG Crossover Management, LLC including:
Track TCG Crossover Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for TCG Crossover Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: TCG Crossover Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For TCG Crossover Management, LLC (SEC CIK: 1839948), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in TCG Crossover Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.